PREDNISONE- prednisone tablet PREDNISONE- prednisone solution PREDNISONE INTENSOL- prednisone intensol solution, concentrate Hikma Pharmaceuticals USA Inc.


PredniSONE Tablets, USP PredniSONE Oral Solution, USP PredniSONE *Intensol*™ Oral Solution (Concentrate)

Rx only

DESCRIPTION

Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder. It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol.

The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione. The structural formula is represented below:



 $C_{21}H_{26}O_5$

M.W. 358.44

Each tablet, for oral administration, contains 1, 2.5, 5, 10, 20, or 50 mg of prednisone. PredniSONE Oral Solution contains 5 mg prednisone per 5 mL, and PredniSONE IntensolTM Oral Solution (Concentrate) contains 5 mg prednisone per mL.

Inactive Ingredients:

PredniSONE Tablets, USP contain the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate and stearic acid (1 mg, 2.5 mg, and 5 mg only).

PredniSONE Oral Solution, USP contains alcohol 5% and the following inactive ingredients: anhydrous citric acid, edetate disodium, fructose, hydrochloric acid, maltol, peppermint oil, polysorbate 80, propylene glycol, saccharin sodium, sodium benzoate,

vanilla flavor and purified water.

PredniSONE Intensol[™] Oral Solution (Concentrate) contains alcohol 30% and the following inactive ingredients: anhydrous citric acid, poloxamer 188, propylene glycol and purified water.

ACTIONS

Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have saltretaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

INDICATIONS

Prednisone tablets and solutions are indicated in the following conditions:

1. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance)

Congenital adrenal hyperplasia

Hypercalcemia associated with cancer

Nonsuppurative thyroiditis

2. Rheumatic Disorders

As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

Psoriatic arthritis

Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)

Ankylosing spondylitis

Acute and subacute bursitis

Acute nonspecific tenosynovitis

Acute gouty arthritis

Post-traumatic osteoarthritis

Synovitis of osteoarthritis

Epicondylitis

3. Collagen Diseases

During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis)

Acute rheumatic carditis

4. Dermatologic Diseases

Pemphigus

Bullous dermatitis herpetiformis

Severe erythema multiforme (Stevens-Johnson syndrome)

Exfoliative dermatitis

Mycosis fungoides

Severe psoriasis

Severe seborrheic dermatitis

5. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:

Seasonal or perennial allergic rhinitis

Bronchial asthma

Contact dermatitis

Atopic dermatitis

Serum sickness

Drug hypersensitivity reactions

6. Ophthalmic Diseases

Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:

Allergic corneal marginal ulcers

Herpes zoster ophthalmicus

Anterior segment inflammation

Diffuse posterior uveitis and choroiditis

Sympathetic ophthalmia

Allergic conjunctivitis

Keratitis

Chorioretinitis

Optic neuritis Iritis and iridocyclitis

7. Respiratory Diseases

Symptomatic sarcoidosis

Loeffler's syndrome not manageable by other means

Berylliosis

Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy

Aspiration pneumonitis

8. Hematologic Disorders

Idiopathic thrombocytopenic purpura in adults

Secondary thrombocytopenia in adults

Acquired (autoimmune) hemolytic anemia

Erythroblastopenia (RBC anemia)

Congenital (erythroid) hypoplastic anemia

9. Neoplastic Diseases

For palliative management of:

Leukemias and lymphomas in adults

Acute leukemia of childhood

10. Edematous States

To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in:

Ulcerative colitis

Regional enteritis

12. Nervous System

Acute exacerbations of multiple sclerosis

13. Miscellaneous

Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy

Trichinosis with neurologic or myocardial involvement

CONTRAINDICATIONS

Systemic fungal infections and known hypersensitivity to components.

WARNINGS

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Immunosuppression and Increased Risk of Infection

Corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can:

- Reduce resistance to new infections
- Exacerbate existing infections
- Increase the risk of disseminated infections
- Increase the risk of reactivation or exacerbation of latent infections
- Mask some signs of infection

Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages.

Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed.

Tuberculosis

If prednisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged prednisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis.

Varicella Zoster and Measles Viral Infections

Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone. In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles:

- If a prednisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered.
- If a prednisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated.

Hepatitis B Virus Reactivation

Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection.

Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

Fungal Infections

Corticosteroids, including prednisone, may exacerbate systemic fungal infections; therefore, avoid prednisone use in the presence of such infections unless prednisone is needed to control drug reactions. For patients on chronic prednisone therapy who develop systemic fungal infections, prednisone withdrawal or dosage reduction is recommended.

Amebiasis

Corticosteroids, including prednisone, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone in patients who have spent time in the tropics or patients with unexplained diarrhea.

Strongyloides Infestation

Corticosteroids, including prednisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Cerebral Malaria

Avoid corticosteroids, including prednisone, in patients with cerebral malaria.

Kaposi's Sarcoma

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi's sarcoma.

Usage in pregnancy

Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy, should be carefully observed for signs of hypoadrenalism.

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.

While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in

patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses.

PRECAUTIONS

General Precautions

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis.

Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation.

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis.

Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed.

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see DOSAGE AND ADMINISTRATION).

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

Convulsions have been reported with concurrent use of methylprednisolone and

cyclosporin. Since concurrent use of these agents results in a mutual inhibition of metabolism, it is possible that adverse events associated with the individual use of either drug may be more apt to occur.

ADVERSE REACTIONS

Fluid and Electrolyte Disturbances

- Sodium retention Fluid retention
- Congestive heart failure in susceptible patients
- Potassium loss
- Hypokalemic alkalosis
- Hypertension

Musculoskeletal

Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones

Gastrointestinal

- Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis **Dermatologic**
- Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests

- ..

Metabolic

Negative nitrogen balance due to protein catabolism

Neurological

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment

Convulsions

Vertigo

Headache

Endocrine

Menstrual irregularities

Development of Cushingoid state

Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness

Suppression of growth in children

Decreased carbohydrate tolerance

Manifestations of latent diabetes mellitus

Increased requirements for insulin or oral hypoglycemic agents in diabetics

Ophthalmic

Posterior subcapsular cataracts

Increased intraocular pressure

Glaucoma

Exophthalmos

Additional Reactions

Urticaria and other allergic, anaphylactic or hypersensitivity reactions

DOSAGE AND ADMINISTRATION

The initial dosage of prednisone may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. **IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT.**

After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

Multiple Sclerosis

In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.)

ADT[®] (Alternate Day Therapy)

ADT is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning. The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children.

The rationale for this treatment schedule is based on two major premises: (a) the antiinflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitaryadrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm. Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity. There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight.

The diurnal rhythm of the HPA axis is lost in Cushing's disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during long-term pharmacologic dose corticoid therapy administered in conventional daily divided doses. It would appear, then, that a disturbance in the diurnal cycle with maintenance of elevated corticoid values during the night may play a significant role in the development of undesirable corticoid effects. Escape from these constantly elevated plasma levels for even short periods of time may be instrumental in protecting against undesirable pharmacologic effects.

During conventional pharmacologic dose corticosteroid therapy, ACTH production is inhibited with subsequent suppression of cortisol production by the adrenal cortex. Recovery time for normal HPA activity is variable depending upon the dose and duration of treatment. During this time the patient is vulnerable to any stressful situation. Although it has been shown that there is considerably less adrenal suppression following a single morning dose of prednisolone (10 mg) as opposed to a quarter of that dose administered every 6 hours, there is evidence that some suppressive effect on adrenal activity may be carried over into the following day when pharmacologic doses are used. Further, it has been shown that a single dose of certain corticosteroids will produce adrenocortical suppression for two or more days. Other corticoids, including methylprednisolone, hydrocortisone, prednisone, and prednisolone, are considered to be short acting (producing adrenocortical suppression for $1\frac{1}{4}$ to $1\frac{1}{2}$ days following a single dose) and thus are recommended for alternate day therapy.

The following should be kept in mind when considering alternate day therapy:

- 1) Basic principles and indications for corticosteroid therapy should apply. The benefits of ADT should not encourage the indiscriminate use of steroids.
- 2) ADT is a therapeutic technique primarily designed for patients in whom long-term pharmacologic corticoid therapy is anticipated.
- 3) In less severe disease processes in which corticoid therapy is indicated, it may be possible to initiate treatment with ADT. More severe disease states usually will require daily divided high dose therapy for initial control of the disease process. The initial suppressive dose level should be continued until satisfactory clinical response is obtained, usually four to ten days in the case of many allergic and collagen diseases. It is important to keep the period of initial suppressive dose as brief as possible particularly when subsequent use of alternate day therapy is intended. Once control has been established, two courses are available: (a) change to ADT and then gradually reduce the amount of corticoid given every other day or (b) following control of the disease process reduce the daily dose of corticoid to the lowest effective level as rapidly as possible and then change over to an alternate day schedule. Theoretically, course (a) may be preferable.
- 4) Because of the advantages of ADT, it may be desirable to try patients on this form of therapy who have been on daily corticoids for long periods of time (e.g., patients with rheumatoid arthritis). Since these patients may already have a suppressed HPA axis, establishing them on ADT may be difficult and not always successful. However, it is recommended that regular attempts be made to change them over. It may be helpful to triple or even quadruple the daily maintenance dose and administer this every other day rather than just doubling the daily dose if difficulty is encountered. Once the patient is again controlled, an attempt should be made to reduce this dose to a minimum.
- 5) As indicated above, certain corticosteroids, because of their prolonged suppressive effect on adrenal activity, are not recommended for alternate day therapy (e.g., dexamethasone and betamethasone).
- 6) The maximal activity of the adrenal cortex is between 2 am and 8 am, and it is minimal between 4 pm and midnight. Exogenous corticosteroids suppress adrenocortical activity the least, when given at the time of maximal activity (am).
- 7) In using ADT it is important, as in all therapeutic situations to individualize and tailor the therapy to each patient. Complete control of symptoms will not be possible in all

patients. An explanation of the benefits of ADT will help the patient to understand and tolerate the possible flare-up in symptoms which may occur in the latter part of the off-steroid day. Other symptomatic therapy may be added or increased at this time if needed.

- 8) In the event of an acute flare-up of the disease process, it may be necessary to return to a full suppressive daily divided corticoid dose for control. Once control is again established alternate day therapy may be re-instituted.
- 9) Although many of the undesirable features of corticosteroid therapy can be minimized by ADT, as in any therapeutic situation, the physician must carefully weigh the benefit-risk ratio for each patient in whom corticoid therapy is being considered.

HOW SUPPLIED

PredniSONE Tablets, USP

1 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 092" debossed on the other side.

NDC 0054-8739-25: 10x10 Unit-Dose

NDC 0054-4741-25: Bottle of 100 Tablets

NDC 0054-4741-31: Bottle of 1,000 Tablets

2.5 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 339" debossed on the other side.

NDC 0054-8740-25: 10x10 Unit-Dose

NDC 0054-4742-25: Bottle of 100 Tablets

5 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 612" debossed on the other side.

NDC 0054-8724-25: 10x10 Unit-Dose

NDC 0054-4728-25: Bottle of 100 Tablets

NDC 0054-4728-31: Bottle of 1,000 Tablets

10 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 899" debossed on the other side.

NDC 0054-0017-20: 10x10 Unit-Dose

NDC 0054-0017-25: Bottle of 100 Tablets

NDC 0054-0017-29: Bottle of 500 Tablets

20 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 760" debossed on the other side.

NDC 0054-0018-20: 10x10 Unit-Dose

NDC 0054-0018-25: Bottle of 100 Tablets

NDC 0054-0018-29: Bottle of 500 Tablets

50 mg - White to off-white, round, biconvex tablet; scored on one side and product identification "54 [above] 343" debossed on the other side.

NDC 0054-0019-20: 10x10 Unit-Dose

NDC 0054-0019-25: Bottle of 100 Tablets

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, child-resistant container as defined in the USP/NF.

PROTECT FROM MOISTURE.

PredniSONE Oral Solution USP, 5 mg per 5 mL

Clear, colorless, slightly viscous solution.

NDC 0054-3722-50: Bottle of 120 mL

NDC 0054-3722-63: Bottle of 500 mL

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF.

PredniSONE Intensol[™] Oral Solution (Concentrate), 5 mg per mL

Clear, colorless, slightly viscous solution.

NDC 0054-3721-44: Bottle of 30 mL with calibrated oral syringe (graduations of 0.25 mL [1.25 mg] to 1 mL [5 mg] on the syringe)

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

Dispense only in the bottle and only with the calibrated oral syringe provided.


Discard opened bottle after 90 days.

Distributed by: **Hikma Pharmaceuticals USA Inc.** Berkeley Heights, NJ 07922

C50000278/04 Revised February 2024

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL


NDC 0054-**8739**-25 10x10 Unit-Dose Tablets **PredniSONE Tablets, USP 1 mg**



NDC 0054-4741-25 100 Tablets PredniSONE Tablets, USP 1 mg




NDC 0054-**8740**-25 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 2.5 mg



NDC 0054-4742-25 100 Tablets PredniSONE Tablets, USP 2.5 mg



NDC 0054-8724-25 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 5 mg




NDC 0054-**4728**-25 100 Tablets PredniSONE Tablets, USP 5 mg



PACKAGE/LABEL PRINCIPAL DISPLAY PANEL


NDC 0054-**0017**-20 10x10 Unit-Dose Tablets **PredniSONE Tablets**, **USP 10 mg**



NDC 0054-0017-25 100 Tablets PredniSONE Tablets, USP 10 mg




NDC 0054-0018-20 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 20 mg




NDC 0054-0018-25 100 Tablets PredniSONE Tablets, USP 20 mg



NDC 0054-0019-20 10x10 Unit-Dose Tablets PredniSONE Tablets, USP 50 mg



NDC 0054-0019-25 100 Tablets PredniSONE Tablets, USP 50 mg



NDC 0054-**3722**-50 120 mL PredniSONE Oral Solution, USP 5 mg per 5 mL

NDC 0054-3722-50 120 mL PredniSONE Oral Solution, USP	prednisone, USP, alcohol 5%. Ickage Insert for formation. -resistant, child-resistant he USP/NF. * to 77°F).	LOT EXP.	2-50 7
5 mg per 5 mL	Roc Roc Roc Roc Roc		0 5 4 - 3 7 2
Distributed by: Hikma R _x only Pharmaceuticals USA Inc. Berkeley Heights, NJ 07922	Each 5 mL contains 5 USUAL DOSAGE: Se Complete Prescribin Dispense in a tight, li container as defined Store at 20° to 25°C [See USP Controlled		c50000266/02

NDC 0054-**3721**-44 30 mL **PredniSONE** *Intensol*[™] **Oral Solution (Concentrate) 5 mg per mL**



Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE (UNII: VB0R961HZT)					REDNISONE ednisone tablet
Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name Ingredient Name Ingredient Name Ingredient Name Ingredient Name					roduct Information
Active Ingredient/Active Moiety Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	DC:0054-4741	ode (Source) ND	Ite	HUMAN PRESCRIPTION DRUG	roduct Type
Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) Ingredient)				ORAL	oute of Administration
Ingredient Name Basis of Strength PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) Ingredient)					
PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT) PREDNISONE Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U) Ingredient Name				Moiety	ctive Ingredient/Active
Inactive Ingredients Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	n Strength	Basis of Strength		dient Name	Ingre
Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	1 mg	PREDNISONE	T)	(PREDNISONE - UNII:VB0R961HZT)	EDNISONE (UNII: VB0R961HZT)
Ingredient Name LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)					
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X) MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)					active Ingredients
MAGNESIUM STEARATE (UNII: 70097M6I30) MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	Strength			Ingredient Name	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)				EWQ57Q8I5X)	CTOSE MONOHYDRATE (UNII:
				097M6I30)	AGNESIUM STEARATE (UNII: 70
				: (UNII: OP1R32D61U)	CROCRYSTALLINE CELLULOS
STARCH, CURN (UNII: 08232NT35J)				J)	ARCH, CORN (UNII: 08232NY3S
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)			42)	(PE A POTATO (UNII: 5856J3G2A2	DIUM STARCH GLYCOLATE T
STEARIC ACID (UNII: 4ELV7Z65AP)					EARIC ACID (UNII: 4ELV7Z65AP

Product Characteristics							
С	olor		WHITE	Score	Score		
Sł	nape		ROUND	Size	Size		
Flavor				Imprint Code		54092	
Contains							
Pa	ackaging						
#	ltem Code		Package Description		Marketing Start Date	Marketing End Date	
1	NDC:0054- 4741-25	100 in 1 BC Combinatio	DTTLE, PLASTIC; T on Product	ype 0: Not a	04/22/1982		
2	NDC:0054- 4741-31	1000 in 1 E Combinatio	OTTLE, PLASTIC; on Product	Type 0: Not a	04/22/1982		
Marketing Information							
Iv	•						
	Marketing Category	Арр	lication Numbe Citat	er or Monograph ion	Marketing Start Date	Marketing End Date	
AN	ANDA ANDA087800			04/22/1982			

DDEDNICONE						
PREDNISONE						
prednisone tablet						
Product Information						
Product Type	HUMAN PRESCI	RIPTION DRUG	ltem C	ode (Source)	NDC	0054-4742
Route of Administration	ORAL					
Active Ingredient/Acti	ve Moietv					
-	gredient Name			Basis of Stre	nath	Strength
PREDNISONE (UNII: VB0R961H				PREDNISONE	ngtii	2.5 mg
PREDNISONE (UNII: VBUR901H	ZI) (PREDNISONE -			PREDNISONE		2.5 mg
Inactive Ingredients						
	Ingredie	nt Name				Strength
LACTOSE MONOHYDRATE (U	NII: EWQ57Q8I5X)					-
MAGNESIUM STEARATE (UNII	: 70097M6I30)					
MICROCRYSTALLINE CELLUL	OSE (UNII: OP1R32	D61U)				
STARCH, CORN (UNII: 08232N	Y3SJ)					
SODIUM STARCH GLYCOLAT	Ε ΤΥΡΕ Α ΡΟΤΑΤΟ	(UNII: 5856J3G2A2)				
STEARIC ACID (UNII: 4ELV7Z6	5AP)					
Product Characteristi	cs					
Color	WHITE	Score		2	pieces	

Sh	nape		ROUND	Size		6mm	
Fla	avor			Imprint Code		54;339	
Contains							
Pa	ackaging						
#	ltem Code		Package Desc	ription	Marketing Start Date	Marketing End Date	
	NDC:0054- 4742-25	100 in 1 BC Combinatio	OTTLE, PLASTIC; Typ on Product	e 0: Not a	04/22/1982		
•		1 6					
M	larketing	Intorm	nation				
	Marketing Category	Арр	lication Number Citatio		Marketing Start Date	Marketing End Date	
AN	DA	ANDA08	37801		04/22/1982		

PREDNISONE						
prednisone tablet						
Product Information						
Product Type	HUMAN PRESCI	RIPTION DRUG	ltem C	ode (Source)	NDC	:0054-4728
Route of Administration	ORAL					
A . I						
Active Ingredient/Activ	ve molety					
Ing	redient Name			Basis of St	rength	Strength
PREDNISONE (UNII: VB0R961H	ZT) (PREDNISONE -	UNII:VB0R961HZT)		PREDNISONE		5 mg
Inactive Ingredients						
	Ingredie	nt Name				Strength
LACTOSE MONOHYDRATE (U	NII: EWQ57Q8I5X)					
MAGNESIUM STEARATE (UNII:	70097M6I30)					
MICROCRYSTALLINE CELLUL	OSE (UNII: OP1R32	D61U)				
STARCH, CORN (UNII: 08232N	Y3SJ)					
SODIUM STARCH GLYCOLATI	Ε ΤΥΡΕ Α ΡΟΤΑΤΟ	(UNII: 5856J3G2A2)				
STEARIC ACID (UNII: 4ELV7Z65	5AP)					
Product Characteristic	s					
Color	WHITE	Score			2 pieces	

Color	VVIIIE	Score	z pieces
Shape	ROUND	Size	6mm
Flavor		Imprint Code	54;612
Contains			

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
NDC:0054- 4728-25100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		04/21/1972		
NDC:0054- 4728-311000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product			04/21/1972	
	4720-31			
	arketing	Information		
			Marketing Start Date	Marketing End Date
M	arketing	Information Application Number or Monograph	-	Marketing End Date

 prednisone tablet

 Product Information

 Product Type
 HUMAN PRESCRIPTION DRUG
 Item Code (Source)
 NDC:0054-0017

 Route of Administration
 ORAL
 VIC:0054-0017

Active Ingredient/Active Moiety					
Ingredient Name	Basis of Strength	Strength			
PREDNISONE (UNII: VB0R961HZT) (PREDNISONE - UNII:VB0R961HZT)	PREDNISONE	10 mg			

Inactive Ingredients

-	
Ingredient Name	Strength
LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
STARCH, CORN (UNII: 08232NY3SJ)	
SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2)	

Product Characteristics							
Color	WHITE	Score		2 pieces			
Shape	ROUND	Size	(6mm			
Flavor		Imprint Code	<u>.</u>	54;899			
Contains							
Packaging							
# Item Code	Package D	escription	Marketing Start Date	Marketing End Date			

1	NDC:0054- 0017-25	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
2	NDC:0054- 0017-29	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
3	NDC:0054- 0017-20	10 in 1 CARTON	02/13/2003	
		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
M	larketing	Information		
	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
AN	IDA	ANDA084122	02/13/2003	

prednisone tablet				
Product Informa	tion			
Product Type	HUMAN P	RESCRIPTION DRUG	Item Code (Source)	NDC:0054-0018
Route of Administra	ation ORAL			
Active Ingredient	Active Moiety			
	Ingredient Na	ame	Basis of St	trength Strength
PREDNISONE (UNII: VBC	DR961HZT) (PREDNIS	ONE - UNII:VB0R961HZT	PREDNISONE	20 mg
Inactive Ingredie	nts			
	Ingr	edient Name		Strength
LACTOSE MONOHYDR	ATE (UNII: EWQ57Q8I	5X)		
MAGNESIUM STEARAT				
MICROCRYSTALLINE C		1R32D61U)		
STARCH, CORN (UNII: C	-			
SODIUM STARCH GLYC	COLATE TYPE A PO	IAIO (UNII: 5856)3G2A2)	
Product Characte	eristics			
Color	WHITE	Score		2 pieces
Shape	ROUND	Size		9mm
Flavor		Imprint Code		54;760
Contains				
Packaging				
				t Marketing End

M	larketing Marketing Category	Information Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
M	larketing	Information		
3		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
3	NDC:0054- 0018-20	10 in 1 CARTON	02/13/2003	
2	NDC:0054- 0018-29	500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	02/13/2003	
	0018-25	Combination Product		

PREDNISONE							
prednisone tablet							
Product Inform	ation						
Product Type		HUMAN PRESC	RIPTION DRUG	ltem C	ode (Source)	NDC	:0054-0019
Route of Administ	ration	ORAL					
Active Ingredie	nt/Active	Moiety					
	Ingre	dient Name			Basis of St	rength	Strength
PREDNISONE (UNII: V	BOR961HZT)	(PREDNISONE -	UNII:VB0R961HZT)		PREDNISONE		50 mg
In a stir o In aread							
Inactive Ingred	ients						Charles an and the
		-	ent Name				Strength
LACTOSE MONOHYD MAGNESIUM STEARA							
MICROCRYSTALLINE			2D61U)				
STARCH, CORN (UNII							
SODIUM STARCH GL		•	(UNII: 5856J3G2A2)				
Product Charac	teristics						
Color	WHI	TE	Score			2 pieces	
Shape	ROL	JND	Size			10mm	
Flavor			Imprint Code			54;343	
Contains							
Packaging							
				Ma	koting Start	Mark	oting End
# Item Code	Pa	ickage Deso	cription	Ma	rketing Start Date	Mark	eting End Date

	Harketing Marketing Category	Information Application Number or Monograph Citation ANDA084283	Marketing Start Date 03/14/2003	Marketing End Date
Μ	Marketing	Application Number or Monograph		-
Μ	larketing	Information		
2	NDC:0054- 0019-25	100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	03/14/2003	
1		10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
	0019-20	10 in 1 CARTON	03/14/2003	

PREDNISONE prednisone solution						
Product Informatio	n					
Product Type		HUMAN PRESCRIPTION DRUG	ltom	Code (Source)		C:0054-3722
		ORAL	item	code (Source)		2.0031 3722
Route of Administratio	on	UKAL				
Active Ingredient/A	ctive	Moiety				
	Ingred	ient Name		Basis of Streng	yth	Strength
PREDNISONE (UNII: VB0R96	61HZT)	(PREDNISONE - UNII:VB0R961HZT)		PREDNISONE		5 mg in 5 mL
Inactive Ingredients	S					
		Ingredient Name			S	trength
ALCOHOL (UNII: 3K9958V90						
ANHYDROUS CITRIC ACID	-	· ·				
EDETATE DISODIUM (UNII:		.C86K)				
FRUCTOSE (UNII: 6YSS42V						
HYDROCHLORIC ACID (UN		7582CB)				
MALTOL (UNII: 3A9RD92BS4						
PEPPERMINT OIL (UNII: AV						
POLYSORBATE 80 (UNII: 6						
PROPYLENE GLYCOL (UNII						
SACCHARIN SODIUM (UNII						
SODIUM BENZOATE (UNII:	-	=5EU)				
WATER (UNII: 059QF0K00R)	.)					
Packaging						
# Item Code	Pao	kage Description	Ma	rketing Start Date	Marl	ceting End Date
1 NDC:0054-3722- 63 Product		TTLE; Type 0: Not a Combination	11/08	/1984		

2 NDC:0054-3722- 50	120 mL in 1 BOTTLE; Type 0: Not a Combination Product	12/13/1996	
Marketing	Information		
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA088703	11/08/1984	

PREDNISO prednisone inte						
Product Info	ormation					
Product Type		HUMAN PRESCRIPTION DRUG	ltem	Code (Source)	ND	C:0054-3721
Route of Admi	nistration	ORAL				
Active Ingree	dient/Active	Moiety				
	Ingred	lient Name		Basis of Streng	yth	Strength
PREDNISONE (UN	NII: VBOR961HZT)	(PREDNISONE - UNII:VB0R961HZT)		PREDNISONE		5 mg in 1 mL
Inactive Ingr	redients					
		Ingredient Name			S	Strength
ALCOHOL (UNII: 3	•					
ANHYDROUS CIT	-	-				
POLOXAMER 188		•				
PROPYLENE GLY	-	Q167V3)				
WATER (UNII: 059	9QF0KO0R)					
Packaging						
# Item Code	Pa	ackage Description	I	Marketing Start Date	Ма	rketing End Date
1 NDC:0054- 3721-44	30 mL in 1 BOT of Co-Package	FLE, GLASS; Type 1: Convenience K	Cit 0	2/20/1985		
Marketing	Informat	ion				
Marketing	Applica	tion Number or Monograph	м	arketing Start	Ма	rketing End

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA088810	02/20/1985	

PREDNISONE

Ρ	roduct Info	rmation						
Pı	roduct Type		HUMAN PR	ESCRIPTION DRUG	ltem Code	(Source)	NDC:	0054-8739
	oute of Admin	istration	ORAL					
4	ctive Ingred	ient/Activ	ve Moiety					
		Ing	gredient Nai	ne	Ba	asis of Stre	ength	Strengt
PR	EDNISONE (UNI	I: VB0R961H	ZT) (PREDNISOI	NE - UNII:VB0R961HZT)	PRE	DNISONE		1 mg
In	active Ingre	edients						
			-	dient Name				Strength
				X)				
	AGNESIUM STE							
				K32D61U)				
	ARCH, CORN (L		-					
SC	DIUM STARCH	GLYCOLAIR						
ст				ATO (UNII: 5856J3G2A2)				
ST	EARIC ACID (UN			ATO (UNII: 5856J3G2A2)				
		NII: 4ELV7Z65	5AP)	ATO (UNII: 5856J3G2A2)				
Pı	roduct Char	NII: 4ELV7Z65	5AP) C S					
Pı Co	roduct Char	acteristic	5AP) C S WHITE	Score			2 pieces	
Pı Ca Sł	r oduct Char blor hape	acteristic	5AP) C S	Score Size		e	ômm	
Pı Co Sł	r oduct Char blor nape avor	acteristic	5AP) C S WHITE	Score		e		
Pı Co Sł	r oduct Char blor hape	acteristic	5AP) C S WHITE	Score Size		e	ômm	
Pı Ca Sł Fla Ca	r oduct Char blor hape avor ontains	acteristic	5AP) C S WHITE	Score Size		e	ômm	
Pı Ca Sł Fli	roduct Char blor hape avor ontains ackaging	vil: 4ELV7Z65	5AP) CS WHITE ROUND	Score Size Imprint Code	Markoti	6	54092	ating End
Pi St Fla Co	r oduct Char blor hape avor ontains	vil: 4ELV7Z65	5AP) C S WHITE	Score Size Imprint Code	Marketin Da	e 5 ng Start	54092 Marke	eting End Date
Pi Ca Sh Fli Ca Pi	roduct Char blor hape avor ontains ackaging	vil: 4ELV7Z65	5AP) CS WHITE ROUND Package De	Score Size Imprint Code		e 5 ng Start	54092 Marke	-
Pi Cc Sh Fli Cc Pi #	roduct Char olor hape avor ontains ackaging Item Code NDC:0054-	III: 4ELV7Z65	5AP) CS WHITE ROUND Package De	Score Size Imprint Code	Da	e 5 ng Start	54092 Marke	-
Pi Cc Sh Fli Cc Pi #	roduct Char olor hape avor ontains ackaging Item Code NDC:0054-	III: 4ELV7Z65 acteristic	5AP) CS WHITE ROUND Package De	Score Size Imprint Code	Da	e 5 ng Start	54092 Marke	-
Pi Sh Fli Cc Pi 1	roduct Char olor hape avor ontains ackaging Item Code NDC:0054-	All: 4ELV7Z65 acteristic 10 in 1 CAR 10 in 1 BLIS Product	SAP) CS WHITE ROUND Package De TON STER PACK; Typ	Score Size Imprint Code	Da	e 5 ng Start	54092 Marke	-
Pi Co Fli Co Pi # 1	roduct Char olor hape avor ontains ackaging Item Code NDC:0054- 8739-25	All: 4ELV7Z65 acteristic 10 in 1 CAR 10 in 1 BLIS Product	SAP) SAP) SAP) SAP) SAP) SAP SAP	Score Size Imprint Code	Da 04/22/1982 Marketi	e 5 ng Start	54092 Mark	-

PREDNISONE prednisone tablet

-							
PI	oduct Type		HUMAN PRES	SCRIPTION DRUG	Item Code (Source)	NDC	:0054-8740
Ro	oute of Admin	istration	ORAL				
Δ	ctive Ingred	ient/Activ	e Moietv				
			redient Nam		Basis of St	ronath	Strengt
PR	EDNISONE (UNI	-		E - UNII:VB0R961HZT)	PREDNISONE	iciigiii	2.5 mg
			, (11221113-0111		The bill of the		2.5 mg
In	active Ingre	edients					
			-	ient Name			Strength
	CTOSE MONOH						
	AGNESIUM STE	· ·	· · ·				
	CROCRYSTALLI			32D61U)			
	ARCH, CORN (U		•				
	EARIC ACID (UN			FO (UNII: 5856J3G2A2)			
Pı	roduct Char	acteristic	5				
	roduct Char		S <i>I</i> HITE	Score		2 pieces	
Co		W	-	Score Size		2 pieces 6mm	
Cc Sł	olor	W	<i>I</i> HITE			-	
Cc Sł Fla	olor Nape	W	<i>I</i> HITE	Size		6mm	
Ca Sł Fla Ca	olor nape avor	W	<i>I</i> HITE	Size		6mm	
Co Sh Fla Co Pa	olor Iape avor Intains	M R	<i>I</i> HITE	Size Imprint Code	Marketing Start Date	6mm 54;339 Mark	eting End Date
Co Sh Fli Co Pi	olor hape avor ontains ackaging	M R	AHITE OUND	Size Imprint Code		6mm 54;339 Mark	
Co Sh Fli Co Pi	olor hape avor ontains ackaging item Code NDC:0054-	W R 10 in 1 CART	AHITE OUND Package Des ON	Size Imprint Code	Date	6mm 54;339 Mark	
Co Sh Fli Co Pi #	olor hape avor ontains ackaging item Code NDC:0054-	W R 10 in 1 CART 10 in 1 BLIST	AHITE OUND Package Des ON	Size Imprint Code	Date	6mm 54;339 Mark	
Cc Sh Fli Cc Pi # 1	olor hape avor ontains ackaging item Code NDC:0054-	M R 10 in 1 CART 10 in 1 BLIST Product	AHTE OUND Package Des ON FER PACK; Type	Size Imprint Code	Date	6mm 54;339 Mark	
Cc Sh Fli Cc Pi #	olor hape avor ontains ackaging item Code NDC:0054- 8740-25	M R 10 in 1 CART 10 in 1 BLIST Product	AHITE OUND Package Des ON FER PACK; Type	Size Imprint Code Solution Stription O: Not a Combination	Date	6mm 54;339 Mark	

PREDNISONE prednisone tablet			
Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0054-8724

٨	tive Ingred	iont/Acti	ivo Moioty				
AC	Live Ingreu		-				<u> </u>
			gredient Nar		Basis of S	otrengtn	Strength
PRI	EDNISONE (UNI	I: VBUR961H	12 T) (PREDNISON	NE - UNII:VB0R961HZT)	PREDNISONE		5 mg
Ina	active Ingre	edients					
			Ingree	dient Name			Strength
LAC	стоѕе молон	YDRATE (U	INII: EWQ57Q8I5>	X)			
MA	GNESIUM STEA	ARATE (UNII	: 70097M6I30)				
міс	CROCRYSTALLI	NE CELLUL	OSE (UNII: OP1	R32D61U)			
	ARCH, CORN (U		-				
				TO (UNII: 5856J3G2A2)			
STE	EARIC ACID (UN	III: 4ELV7Z6	5AP)				
Pr	oduct Char	acteristi	cs				
Co	lor		WHITE	Score		2 pieces	
Sh	аре		ROUND	Size		6mm	
Fla	vor			Imprint Code		54;612	
Co	ntains						
Pa	nckaging						
Pa #	ackaging Item Code		Package De	escription	Marketing Start Date		eting End Date
#		10 in 1 CAF	-	escription			-
#	Item Code		RTON	escription	Date		-
# 1 [Item Code	10 in 1 BLI	RTON		Date		-
# 1 [1	Item Code	10 in 1 BLI Product	RTON STER PACK; Type		Date		-
# 1 [1	Item Code NDC:0054- 8724-25	10 in 1 BLI Product	RTON STER PACK; Type Nation		Date	t Mark	-

Labeler - Hikma Pharmaceuticals USA Inc. (080189610)

Establishment			
Name	Address	ID/FEI	Business Operations
West-Ward Columbus Inc.		058839929	MANUFACTURE(0054-4741, 0054-4742, 0054-4728, 0054-0017, 0054-0018, 0054-0019, 0054-3722, 0054-3721, 0054-8739, 0054-8740, 0054-8724)